药明生物交流纪要:上调增长预期,公司现金流充沛,没有融资需求

Buffett读书会
Yesterday

继双抗、ADC之后,下一个热点将是mRNA【2025H1投资交流问答纪要】Q:业绩增长预期?A:1、R-D-M三个引擎全面发力,M业务势头依然强劲,截至今年上半年,2026年PPQ项目排期已达27个。2、利润率提升:多重因素驱动包括R业务、WBS效率提升、产能利用率提高(数个大型商业化项目)。3、强劲的自由现金流凸显优异的盈利质量。4、全球产能布局如期推进:爱尔兰、美国、新加坡进展都非常好,德国的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10